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Reduced Androgen Receptor Expression Accelerates the
Onset of ERBB2 Induced Breast Tumors in Female Mice
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Irina U. Agoulnik1,5*
1 Department of Cellular Biology and Pharmacology, Herbert Wertheim College of Medicine, Florida International University, Miami, Florida, United States of America,
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Abstract
Androgen receptor (AR) is commonly expressed in both the epithelium of normal mammary glands and in breast cancers.
AR expression in breast cancers is independent of estrogen receptor alpha (ERa) status and is frequently associated with
overexpression of the ERBB2 oncogene. AR signaling effects on breast cancer progression may depend on ERa and ERBB2
status. Up to 30% of human breast cancers are driven by overactive ERBB2 signaling and it is not clear whether AR
expression affects any steps of tumor progression in this cohort of patients. To test this, we generated mammary specific Ar
depleted mice (MARKO) by combining the floxed allele of Ar with the MMTV-cre transgene on an MMTV-NeuNT background
and compared them to littermate MMTV-NeuNT, Arfl/+ control females. Heterozygous MARKO females displayed reduced
levels of AR in mammary glands with mosaic AR expression in ductal epithelium. The loss of AR dramatically accelerated the
onset of MMTV-NeuNT tumors in female MARKO mice. In this report we show that accelerated MMTV-NeuNT-dependent
tumorigenesis is due specifically to the loss of AR, as hormonal levels, estrogen and progesterone receptors expression, and
MMTV-NeuNT expression were similar between MARKO and control groups. MMTV-NeuNT induced tumors in both cohorts
displayed distinct loss of AR in addition to ERa, PR, and the pioneer factor FOXA1. Erbb3 mRNA levels were significantly
elevated in tumors in comparison to normal mammary glands. Thus the loss of AR in mouse mammary epithelium
accelerates malignant transformation rather than the rate of tumorigenesis.
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evidence suggests that the most critical partner for ERBB2 driven
epithelial transformation and tumorigenesis is ERBB3. In human
breast cancer cell lines with amplified ERBB2 expression,
depletion of ERBB3 reduces cell proliferation to the same extent
as depletion of ERBB2, while loss of ERBB1 (epidermal growth
factor receptor (EGFR)) does not affect proliferation [4]. The
activated form of ERBB3 was detected in human breast cancers
with amplified ERBB2 expression [4]. Multiple mouse models
overexpressing ERBB2 in mammary glands have been established,
all of which lead to development of mammary tumors [5,6,7].
Similar to human breast cancer, ERBB3 plays a central role in
murine breast cancer models. Ablation of endogenous Erbb3 in
mammary epithelial cells caused a decrease in ERBB2 induced
tumor incidence from 93.3% to 6.7% [8]. In contrast, Erbb4
ablation did not affect latency or histological grade of MMTVNeu mouse mammary tumors [9]. As noted in human cancers,
elevated expression of activated ERBB3 has been detected in
transgenic mice overexpressing activated ERBB2 [10].
Estrogen, progesterone, and androgen receptors (ERa, PR and
AR) are highly expressed in mammary epithelium and are

Introduction
The majority of breast cancers originate in epithelial cells that
line the ducts of the mammary glands. A number of alterations
lead to the development of distinct tumor types from these cells.
Two of the best described and therapeutically exploited drivers of
transformation are estrogen receptor alpha (ERa) and v-erb-b2
erythroblastic leukemia viral oncogene homolog 2, neuro/
glioblastoma derived oncogene homolog (avian), ERBB2, also
known as human epidermal growth factor receptor 2 (HER2/
Neu). However, additional markers are sought that denote
molecular signatures that are better able to predict tumor
progression, therapeutic response, and probability of recurrence.
According to different reports, 15 to 30% of breast cancers are
driven by overexpression of ERBB2 [1,2]. ERBB2 is part of a
complex network comprised of four receptor tyrosine kinases
(RTK), ERBB1-4. They can be bound by a variety of peptide
hormones which cause receptors to homo- and/or heterodimerize
and become active. ERBB2 does not have a ligand and is activated
by partnering with itself or other family members [3]. Recent
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essential for mammary gland development, function, and carcinogenesis. ERa inhibitors, such as tamoxifen, have been a
mainstay of cancer prevention trials [11]. Aromatase inhibitors
that block conversion of androgens to estrogens have been shown
to protect against breast cancer progression in patients positive for
ERa and PR [12,13,14]. Both ERa and PR are positive prognostic
markers in breast cancer and their loss is associated with poor
prognosis. Mouse models with either Esr1 or Pr genes knocked out
fail to develop functional mammary glands [15,16] and both
receptors are required for mouse mammary tumorigenesis [17,18].
AR is expressed in the epithelium of the normal mammary
gland and in approximately 70–90% of invasive breast cancers, a
frequency comparable to that of ERa (70–80%) or PR (50–70%)
[19]. In both normal and malignant human breast tissue there are
cells that are positive for AR and ERa and cells that only express
AR [20]. The role of AR in breast cancer is currently unclear and
seems to depend on the cellular milieu. The expression of AR in
ERa positive tumors is associated with less aggressive tumors and a
more favorable prognosis [21]. However, AR expression in ERa
negative and triple negative tumors is associated with poor
prognosis and increased mortality [21]. In ERa negative breast
cancer, ERBB2 overexpression significantly correlates with high
AR and ERBB3 expression [22,23,24]. In MDA-MB-453 breast
cancer cells that do not express ERa, AR activates ERBB2
signaling by direct androgen-dependent induction of WNT7B and
ERBB3 expression [22]. In mouse models, stimulation of AR
signaling mid-puberty suppressed epithelial proliferation and
development of ductal extensions [25]. Global AR knockout
significantly increased the susceptibility of the mammary gland to
the chemical carcinogen, DMBA, presumably by elevating
estrogenic activity [26].
Since AR is frequently expressed in ERBB2 amplified tumors,
we asked how the loss of AR signaling would affect tumor
incidence and progression in this cohort. We described here
analysis of breast tumorigenesis in mice with overexpression of an
activated form of ERBB2 and conditional deletion of the Ar allele
specifically in the mammary gland epithelium (MARKO).
Remarkably, the first tumors in female MARKO mice were
detected almost 100 days earlier than in control mice. Similar to
human ERBB2 driven breast cancer, tumors in ERBB2 transgenic
animals show simultaneous increase in endogenous ERBB3 but
not ERBB4 expression [8,22,27,28]. We observed that tumors in
both control and MARKO mice showed reduced gene expression
of the steroid receptors Era, Pr, Ar and their pioneer factor Foxa1.
Our data suggest that ERBB2/ERBB3 driven tumorigenesis is
opposed by AR and its loss results in earlier tumor development.

chased from Jackson Laboratories (Bar Harbor, ME, USA). Mice
with floxed exon 2 of the X chromosomal androgen receptor gene
(Arfl) were described previously [30]. Deletion of Exon 2 causes a
frame shift and production of an unstable amino-terminal
fragment, completely lacking the DNA binding domain. Transgenic mice were genotyped by PCR from genomic DNA isolated
by ear punches with primers specific to the ERBB2 and cre
transgenes and wild-type, floxed and deleted (ArD) Ar alleles as
described in the original publications. MMTV-cre, MMTVNeuNT, Arfl/+ females and MMTV-cre, MMTV-NeuNT, Arfl/Y
males (MARKO, mammary gland specific AR knockout) and
control MMTV-NeuNT, Arfl/+ females and MMTV-NeuNT,
Arfl/Y males were produced according to the breeding scheme
shown in Figure 1.

Incidence and Survival Study
MARKO females (n = 19) and males (n = 33) and littermate
controls (females, n = 29; males, n = 31) were used in the survival
study. All females were kept as virgins for the entire period of
study. Mice were palpated at least twice a week to detect tumors.
Tumor bearing mice were kept until they met euthanasia criteria
which included tumor burden of 10% of the body weight or more,
significant loss of weight, visible signs of distress, huddled posture,
immobility, moribund appearance. The age of mice when a tumor
was first detected (incidence) and the age of mice when euthanized
due to tumor burden (survival) were recorded. At the time of
euthanasia serum was collected, tumors and mammary glands
were removed for histological analysis, RNA and DNA isolated,
and other organs were examined for metastases. All female mice
were sacrificed at 400 days of age and at 450 days for males.
Kaplan-Meier survival plots were generated and compared by
Log-rank test statistical analyses using GraphPad Prism software
(GraphPad Software, San Diego, CA). P,0.05 was considered
statistically significant.

Histology and Immunohistochemistry
Mammary glands and tumors were fixed in 4% paraformaldehyde at 4uC overnight. Deparaffinized 5 mm sections of both
tumors and normal mammary glands were immunostained for
ERa, AR, ERBB2, and Ki67. All washes were done in TBS with
0.05% Tween-20. Antigen retrieval for ERBB2 was achieved by
boiling for one minute, followed by fifteen minutes at 90uC in
1 mM EDTA pH 8.0. ERa and AR antigen retrieval was done by
heating to 99uC in pH 6.0 10 mM sodium citrate buffer for fifteen
minutes, with the addition of 1 mM EDTA for AR. Endogenous
peroxidase activity was blocked using 1% H2O2 in methanol for
ten minutes. Endogenous biotin was blocked using the Avidin/
Biotin Blocking Kit (Vector Laboratories, Burlingame, CA),
followed by blocking with 10% normal goat serum in TBS for
45 minutes. Immunostaining for AR (RB-1358, 1:50, Neomarkers,
Fremont, CA), ERa (SC-542, 1:250, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA), and ERBB2 (mAB#4290, 1:100, Cell
Signaling Technology, Danvers, MA) were performed overnight at
4uC diluted in 3% BSA in TBS. Ki67 sections were incubated in
primary antibody (RB-1510-P1, 1:100, Neomarkers) in TBS for
one hour at room temperature. AR, ERa, and ERBB2 stained
sections were incubated with biotinylated goat anti-rabbit secondary antibody for 30 min at room temperature and then with
streptavidin conjugated peroxidase for 30 min at room temperature. Ki67 was labeled using the Vectastain ABC kit (Vector
Laboratories, Burlingame, CA). Staining was developed for all
proteins using the ImmPACT DAB Peroxidase Substrate Kit
(Vector Laboratories) and all slides were counterstained with
haematoxylin.

Methods
Animal Breeding and Genotyping
Animal studies were conducted in accordance with the humane
standards of animal care, as outlined in the US National Institutes
of Health Guide for the Care and Use of Laboratory Animals and
all procedures were approved by the Florida International
University Institutional Animal Care and Use Committee. All
mice were maintained in a temperature controlled room, with 12h light, 12-h dark photocycle and fed Teklad global 18% protein
rodent diet chow (Harlan, Indianapolis, IN) and fresh water ad
libitum. Transgenic mice (FVB-Tg(MMTV-ErbB2)NK1Mul/J)
containing the activated rat ERBB2 oncogene targeted to the
mammary epithelium by the MMTV-LTR promoter (hereafter
referred to as MMTV-NeuNT) [7] and mice with the Cre
recombinase transgene under the control of the MMTV-LTR
promoter (Tg(MMTV-cre)1Mam/J, MMTV-cre) [29] were purPLOS ONE | www.plosone.org
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Figure 1. Characterization of mice with conditional knockout of AR in mammary glands (MARKO). A. Breeding strategy used to create
experimental cohorts. Two generation breeding was used to produce tumor-prone MMTV-NeuNT (activated rat ERBB2) transgenic MARKO (male and
females underlined on the left side) and Control (underlined on the right) mice. MARKO mice are positive for MMTV-cre transgene, specifically
expressed in mammary glands. B. Recombination events in the genomic DNA from mammary ductal tissue dissociated from fat cells. Top band
(952 bp) is derived from the non-recombined floxed Arfl allele, middle band (855 bp) is from the wild-type Ar+ allele, and the lower band (404 bp) is
an amplicon derived from the ArD allele, resulting from Cre/LoxP induced deletion of exon 2. Arfl/+ is a positive control for the floxed allele and WT is
wild-type (Ar+/Ar+). Left panel is recombination in male mice and the right panel is recombination in female mice. No recombination is observed in
mice lacking MMTV-cre (lanes 1 and 4), the deleted allele is present in mice with MMTV-cre (lanes 2 and 3) C. Reduced number of AR positive luminal
epithelial cells in MARKO mammary glands. AR positive luminal epithelial cells in the mammary glands of Control (n = 5) and MARKO (n = 5) mice were
counted and determined as a percentage of the total number of cells per gland (p = 0.0019). An average of 260 cells were counted per individual
mouse. Immunohistochemical staining for AR expression in Control (D) and MARKO (E and F) mammary glands. Scale bar = 20 mm.
doi:10.1371/journal.pone.0060455.g001

DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA) and the
remaining cells were resuspended in TRIzol reagent (Life
Technologies, Grand Island, NY). RNA was extracted according
to the manufacturer’s instructions. Five micrograms of total RNA
was reverse transcribed to cDNA using the GoScript cDNA
synthesis kit (Promega, Madison, WI). Quantitative PCR analysis
of gene expression was performed using Roche Universal
ProbeLibrary assays on a Roche 480 LightCycler. For a complete
list of primers see Table S1.

Ki67 staining was quantified by counting the number of Ki67
stained cells in random fields of a total of .300 cells. Final counts
were expressed as a percentage of cells positive for Ki67. AR
staining was quantified by counting the number of positively
stained luminal epithelial cells from randomly selected ducts. AR
staining was determined as a percentage of the total number of
luminal epithelial cells.

Tissue Preparation and Gene Expression Analysis
Largest cellular compartment of the mouse mammary gland is
fat. To remove fat cells, excised mammary glands were incubated
in 1% w/v collagenase (Roche, Mannheim, Germany) dissolved in
Earle’s Balanced Salt Solution at 37uC with constant agitation for
1 hour. Dissociated tissue was centrifuged at 1000 rpm for 5 min
and upper layer of fat cells and overlaying buffer removed. An
aliquot of pelleted cells was taken for DNA extraction using
PLOS ONE | www.plosone.org

Hormone Analysis
Mice were anesthetized by isoflurane inhalation (Webster
Veterinary, Devens, MA), and blood collected by ocular orbital
bleeding. Serum was isolated by centrifugation and stored at –
20uC until analysis. Testosterone and estradiol measurements were
performed by radioimmunoassay (RIA) and ELISA (Calbiotech,
3
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San Diego, CA) respectively in the University of Virginia Center
for Research in Reproduction Ligand Assay and Analysis Core
(University of Virginia, Charlottesville). Sensitivity of the testosterone RIA assay was 10 ng/dL. Sensitivity of the estradiol ELISA
assay was 7 pg/ml.

onset (273618.36 days) compared to their control littermates
(352.568.263 days, P = 0.0005) (Figure 3B). To evaluate whether
loss of AR affected survival, females were sacrificed when tumors
grew to approximately 1.5 cm in diameter, an animal had multiple
tumors, or showed signs of morbidity, and the survival curves were
calculated. The similar average size of tumors in the two groups
(Control = 1.9160.27 g and MARKO = 1.7160.47 g) demonstrated that the mice were sacrificed without preferential selection.
Concordantly with an earlier onset of tumors, the survival rate in
MARKO females within the first 375 days was significantly
reduced (P = 0.0208, Log-rank Test). However, no significant
difference was observed in the survival rate between control and
MARKO mice during the full course of this study (400 days)
(Figure 3C, P = 0.2376). Similar numbers of females in both
groups (36.84% (7/19) in MARKO versus 27.58% (8/29) in
Control) developed lethal cancer within the period of the study.
The time between tumor detection and euthanasia between two
groups was slightly lower in the Control group, however the
difference was not statistically significant (Figure 3D). At 400 days,
2 female control mice were determined to have small mammary
tumors, while no MARKO mice had detectable tumors. Therefore
at the completion of the study, 58.6% (17/29) of control mice and
63.16% (12/19) of MARKO females were tumor free. Similar
numbers of tumor-bearing mice in the two groups had multiple
tumors (41.6%, 5/12 in Control and 43.8%, 3/7 in MARKO).
Although MARKO females displayed an earlier onset of MMTVNeuNT tumors, the cell proliferation index evaluated by Ki67
staining in tumors isolated at sacrifice was similar in both groups
(Fig. S1). Histological analysis of tumors showed that tumors were
poorly differentiated and had a uniform morphology comprised of
compact adenocarcinoma cells, characteristic for this model [7]
with limited portions of intratumoral stroma (Figure 3E and F).
Histological grading of the tumors was similar between both
groups (Table 1). No metastases were detected in our experiments.
Previously it was shown that MMTV-NeuNT caused the
development of mammary tumors in male mice [7]. In our study
only 10.9% of males developed tumors within 450 days, including
2/33 in the MARKO group (,6%) and 5/31 in the control group
(,16%), and of these mice only 3 were sacrificed due to tumor
burden. PCR analysis showed the presence of deleted ArD allele in
all samples of genomic DNA isolated from MARKO male
mammary glands (Figure 1B). The low number of tumor-bearing
mice during the course of this study prevented further evaluation
of the role of AR deletion in MMTV-NeuNT male mice.

Statistical Analysis
Student t-test for two groups and one-way ANOVA for multiple
group comparisons were used to assess significance of differences.
Differences were expressed as mean 6SEM; P,0.05 was
considered significant. Tumor incidence data was analyzed using
Gehan-Breslow-Wilcoxon test. All analyses were performed using
the GraphPad Software package.

Results
Female MARKO Mice Display a Mosaic Pattern of AR
Expression in the Mammary Gland
To assess the role of the AR in ERBB2 driven tumorigenesis, we
crossed MMTV-cre, MMTV-NeuNT mice with Arfl/fl mice to
obtain MMTV-cre, MMTV-NeuNT, Arfl/+ (or Arfl/Y males)
MARKO mice and MMTV-NeuNT, Arfl/+ female (or Arfl/Y
males) control littermates (Figure 1A). The generation of
homozygous ArD female mice was not possible under the current
breeding strategy, since MMTV-cre, MMTV-NeuNT, Arfl/Y
males, required for this breeding (Figure 1A), were infertile and
displayed an under-masculinized phenotype due to Ar ablation in
several male reproductive organs. This phenotype is similar to that
observed for other ARKO models [30,31,32]. MMTV-Cre
induced recombination of the Arfl allele resulting in deletion of
exon 2 was confirmed by PCR analysis of MARKO genomic
DNA isolated from partially dissociated mammary glands
(Figure 1B). The deleted allele was detected in all Arfl/+ females
and Arfl/Y males with the MMTV-Cre transgene. Due to X
chromosome inactivation in females, a single allele of Ar, either
control or exon 2– deleted, is expressed in each individual cell.
This means that MARKO mammary epithelium is a mix of cells
expressing normal levels of Ar and cells with no Ar expression. We
counted AR positive luminal epithelial cells (Figure 1C) and found
that the percentage of cells positively stained for AR in MARCO
(,32%) mammary glands was significantly lower than in controls
(,68%) (p = 0.0019). AR nuclear staining was detected in the
mammary glands of both control and MARKO female mice.
Nuclear AR staining was observed in the majority of luminal
epithelial cells in the mammary glands of control females
(Figure 1C and D). Varying frequency of AR expression was
observed in MARKO (Figure 1C, E and F) mice, which showed a
reduced percentage of positive AR nuclear staining in luminal
epithelial cells. AR staining was observed in approximately 32% of
cells. AR staining in adipose tissue was unaffected in all MMTVcre mice.
Global knockout of Ar in female mice was previously shown to
increase luminal epithelial cell proliferation [26]. In our conditional knockout model, we observed similar luminal epithelial cell
proliferation in female MARKO and control mice (Figure 2).

AR does not Suppress Mammary Gland Mitogenic
Signaling Pathways
To determine if AR loss influenced hormone status in our
model we evaluated the serum concentrations of estradiol and
testosterone. No changes in serum estradiol or testosterone levels
were detected between control and MARKO mice (Figure 4A and
4B). Expression of Esr1, Pr and downstream target genes of both
receptors: amphiregulin (Areg), receptor activator of nuclear factor
kappa-B ligand (Rankl), and wingless-type MMTV integration site
family, member 4 (Wnt4) were also unchanged in non-tumor
bearing mammary glands of MARKO mice compared to controls
(Fig. S2).
In both MARKO and control mice, Errb2 transgene expression
was dramatically increased in tumors compared to normal nontumor bearing mammary glands from the same animals
(Figure 4C). Elevated Erbb2 expression was similar in both
MARKO and control tumors (p = 0.2197). Increased ERBB2
protein levels were detected in tumors (Figure 4D and 4E

Diminished AR Expression Promotes an Early Onset of
ERBB2 Tumors
The first tumors in MARKO mice were observed almost 100
days prior to the appearance of palpable tumors in control mice
(Figure 3A). AR deficiency in the mammary glands of female mice
dramatically accelerated the onset of MMTV-NeuNT driven
tumors. In female mice that developed tumors within 400 days,
MARKO mice had a significantly lower average age of tumor
PLOS ONE | www.plosone.org
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Figure 2. Control and MARKO mice show similar proliferation in the normal mammary gland. Representative pictures of normal Control
(A) (n = 4) and MARKO (B) (n = 4) mammary glands stained for Ki67. Arrowheads denote Ki67 positive cells. C. Ki67 staining was quantified and is
shown as the percentage of total epithelial cells positive and negative for Ki67 staining. Scale bar = 20 mm.
doi:10.1371/journal.pone.0060455.g002

tumors (Figure 4I) (normal versus tumor in Control p = 0.0310 and
MARKO p = 0.0272). No significant difference was noted
between tumors from the two groups. This suggests that Erbb3 is
selectively upregulated to cooperate with ERBB2 driven tumorigenesis.

compared to 4F and 4G), corresponding to the elevated mRNA
levels.
Overexpression of ERBB2 in human patients is associated with
elevated expression or activity of ERBB3 [22]. Elevated levels of
ERBB3 protein have been noted in tumors of ERBB2 transgenic
mice [10]. We compared the expression of Erbb3 in tumors from
control and MARKO mice to non-tumor bearing mammary
glands. Strikingly, increased expression of ERBB2 was associated
with 18 to 20 fold increased expression of endogenous Erbb3
(Figure 4H). Loss of Ar in MARKO mice did not alter increased
Erbb3 expression. To evaluate whether Erbb3 upregulation in
MMTV-NeuNT tumors was selective or whether these tumors
displayed elevated expression of other ERBB family members, we
also examined the expression of Erbb4. Expression of Erbb4 in both
normal cohorts was similar and was significantly reduced in

ERa and PR Signaling is Maintained during AR Loss in
Ductal Epithelium
Hormonal independence of breast cancer can occur with
disease progression and induction of ERBB2 signaling [33,34].
Therefore we evaluated the expression of sex steroid receptors in
tumors obtained from control and MARKO mice and compared
them to each other and to non-tumor bearing mammary glands.
Ar expression was significantly reduced in MARKO tumors
compared to tumors from control mice (Figure 5A). In addition,

Table 1. Histopathological tumor grading in Control and MARKO mice.

Mouse #

Genotype

Necrosis

Mitosis per 40X (field diameter 0.44 mm)

Grade

C424

Control

Extensive

8

High

C589

Control

Extensive

5

High

C745

Control

None

2

Low

C951

Control

None

1

Low

C756

Control

Focal

2

Low

C764

Control

None

2

Low

C779

Control

None

1

Low

C786

Control

Focal

1

Low

C410

Control

Tumor was too small and was used up for RNA analysis

C299

MARKO

None

1

C472

MARKO

Focal

5

High

C582

MARKO

None

1

Low

C658

MARKO

Focal

4

High

C775

MARKO

Focal

3

Low

C777

MARKO

Focal

1

Low

C755

MARKO

Focal

4

High

C754

MARKO

Tumor was too small and was used up for RNA analysis

Low

Mitotic count and presence/absence of necrosis were used as grading criteria in this study. Tumors with a low mitotic count (,4 hpf) and focal (,5%) or no necrosis
correspond to low grade carcinoma while those with a high mitotic rate ($4/5 hpf) and necrosis (.5%) are considered high grade. Low and high grade carcinomas
were detected in both Control and MARKO groups.
doi:10.1371/journal.pone.0060455.t001
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Figure 3. MARKO mice show an earlier onset of breast tumors in MMTV-NeuNT mice. A. Mice were examined two to three times per week
starting at 6 months for the presence of palpable tumors. Age of incidence was recorded as the first day at which a palpable tumor was detected.
Percentage of tumor free mice was plotted versus the age of the mice in days. Hazard ratio = 0.2340 and 95% CI ratio of = 0.06054 to 0.9047. B. Mean
age of tumor incidence was calculated for tumor bearing MARKO (273+/218.36 days, n = 7) and control (352.5+/28.263 days, n = 10) mice, p = 0.0005.
C. Survival of MARKO and Control MMTV-NeuNT females. Percentage of surviving mice was plotted versus age (p = 0.3499 at 400 days). Hazard
ratio = 0.6023 and 95% CI of ratio = 0.2080 to 1.744. D. Average time in days between tumor detection and sacrifice, due to tumor burden prior to 400
days of age, p = 0.5000. Representative hematoxylin and eosin staining of Control (E) and MARKO (F) tumors. Scale bar = 50 mm.
doi:10.1371/journal.pone.0060455.g003

regardless of genotype, we observed significant loss of Ar
expression in MMTV-NeuNT tumors compared to normal
mammary glands (Figure 5A).

PLOS ONE | www.plosone.org

Similarly to Ar, Esr1 and Pr expression was significantly reduced
in MMTV-NeuNT tumors compared to non-tumor bearing
mammary glands (Figure 5B and C). We observed similar Esr1
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Figure 4. Elevated ERBB2 and ERBB3 expression in Female MMTV-NeuNT tumors. A. Serum obtained at sacrifice from control (n = 11) and
MARKO (n = 10) mice was analyzed for estradiol levels (E2). B. Serum from A was analyzed for testosterone (T) levels. C. MMTV-NeuNT expression. At
the time of sacrifice, tumors were harvested and non-tumor bearing mammary glands were dissociated from the fat pad and RNA was prepared as
described in the methods section. NeuNT expression was analyzed by quantitative RT-PCR and normalized to 18S expression. Expression of NeuNT in
tumors (Control n = 9 and MARKO n = 7) for MARKO and Control mice and normal mammary glands (Control n = 26, MARKO = 15) was normalized to
expression in non-tumor bearing mammary glands of the Control group. D-G. Immunohistochemical detection of ERBB2 in tumors, Control (D) and
MARKO (E) at 40X magnification, and in normal mammary ducts, Control (F) and MARKO (G) at 100X magnification. Gene expression analysis of Erbb3
(H) and Erbb4 (I) in the same samples as in C. *denotes P,0.05, **P,0.01 and ***P,0.005.
doi:10.1371/journal.pone.0060455.g004
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Figure 5. Steroid receptor expression is reduced in MMTV-NeuNT tumors. At the time of sacrifice, tumors were harvested and non-tumor
bearing mammary glands were dissociated from the fat pad. RNA was prepared as described in the methods section. Levels of Ar (A), Esr1 (B), Pr (C)
and 18S were analyzed by quantitative RT-PCR (Control normal = 26, Control tumor = 9, and MARKO normal = 15 and MARKO tumor = 7). Expression of
each receptor was normalized to 18S. Receptors in tumors for MARKO and Control mice and normal MARKO glands were normalized to expression in
non-tumor bearing mammary glands from the Control group. *denotes P,0.05, **P,0.01 and ***P,0.005. Immunohistochemical detection of ERa in
the normal mammary gland (D) of Control mice and tumors from Control (E) and MARKO (F) mice. Immunohistochemical detection of AR in the
normal mammary gland of Control mice (G) and tumors from Control (H) and MARKO (I) mice. Scale bar = 50 mm.
doi:10.1371/journal.pone.0060455.g005

and Pr expression in MARKO tumors and tumors obtained from
control mice (Esr1 p = 0.1020 and Pr p = 0.4385) (Figure 5B and
C). Correlating with reduced mRNA levels of steroid receptors in
tumors, we also observed reduced protein staining for ERa
(Figure 5D–F) and AR (Figure 5G–I) in MMTV-NeuNT tumors.
To confirm reduced steroid receptor signaling in MMTVNeuNT tumors, the expression of known ERa and PR target

PLOS ONE | www.plosone.org

genes (Areg, RankL and Wnt4) were examined. As was observed for
the receptors, expression of these target genes was significantly
reduced in MMTV-NeuNT tumors compared to normal mammary glands (Figure 6). Expression of RankL was elevated in
normal mammary glands of MARKO mice compared to
Controls, although it failed to reach statistical significance
(p = 0.3036). Pr is an ERa target gene and therefore the reduced
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between MMTV-NeuNT expressing and non-expressing mammary glands (Figure 7E).

expression of Pr and downstream genes may be the consequence of
reduced ERa expression. This data further confirms that steroid
receptor signaling is reduced in MMTV-NeuNT tumors. No
significant difference in expression of Areg, RankL, or Wnt4 was
detected between the tumors of control and MARKO mice
(Figure 6). This was consistent with similar levels of Esr1 and Pr
expression in tumors.
Since the steroid receptors themselves were diminished in
MMTV-NeuNT tumors, we examined the status of FOXA1, a
pioneer factor closely associated with ERa and AR function
[35,36] and with ERBB2 expression [37,38]. Interestingly, we
observed a significant loss of Foxa1 expression in tumors
(Figure 6D).

Discussion
To investigate the role of AR in ERBB2 driven tumorigenesis
we created a mouse model that expressed an activated mutant of
rat ERBB2 [7] and were heterozygous for Ar deletion. Due to X
chromosomal inactivation in females the floxed or wild type Ar
allele may be inactivated. In luminal epithelial cells of MARKO
mice where the floxed allele is inactivated, Cre recombinase will
fail to ablate AR and therefore these mice will retain a portion of
cells with normal AR expression. This was reflected in AR
expression analysis of MARKO mammary glands, which
displayed an approximately 30% decrease in Ar at the mRNA
level. We utilized only partial dissociation of the mammary gland
to evaluate gene expression. Therefore, the presence of stromal
cells, vasculature, and some fat cells likely reduced the true extent
of Ar deletion. Possible proliferative advantage of one genotype
over the other and penetrance of MMTV-cre expression may also
contribute to varied recombination frequency. AR histological
staining confirmed that MARKO mice display a significant
reduction in the number of luminal epithelial cells positive for AR.
The current model does not generate complete ablation of Ar
across the entire mammary gland; rather it creates a mixed
population of epithelial cells expressing normal levels of AR and
cells with complete lack of expression. Genetic alterations that give
rise to breast cancer or promote tumor progression are thought to

MMTV-NeuNT Expression does not Affect Steroid
Receptor Status Prior to Tumor Formation
Loss of steroid receptor and Foxa1 expression in MMTVNeuNT tumors indicated that Erbb2 expression drove the loss of
these markers and that their loss may be associated with tumor
etiology. To evaluate whether Erbb2 altered the expression of these
genes prior to tumor formation, we compared their expression in
normal mammary glands from MMTV-NeuNT expressing mice
and nontransgenic mice with the same mixed genetic background
(minus MMTV-NeuNT). Expression of the rat Erbb2 transgene
was detected only in MMTV-NeuNT mice (Figure 7A). No
significant change in Ar, Esr1, or Pr expression was observed
(Figure 7B, 7C, and 7D). Foxa1 showed no change in expression

Figure 6. Downstream targets of steroid receptors are reduced in MMTV-NeuNT tumors. Tumors and non-tumor bearing mammary
glands were evaluated for the expression of ERa and PR downstream target genes. Expression of each gene was normalized to 18S. Gene expression
in tumors for MARKO and Control mice and normal MARKO glands were normalized to expression in non-tumor bearing control mammary glands
(Control normal = 26, Control Tumor = 9, MARKO normal = 15 and MARKO tumor = 7). Reduced expression was seen in tumors compared to normal
tissue for Areg (A), Rankl (B), Wnt4 (C) and Foxa1 (D). ***P,0.005, for normal versus tumor expression.
doi:10.1371/journal.pone.0060455.g006
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significant change in proliferation rates, the possibility that
MARKO mice have elevated proliferation in the AR depleted
luminal epithelium during estrus cannot be excluded.
Inhibition of AR signaling by the antagonist flutamide in
postpubertal mice significantly increased proliferation of mammary epithelial cells [25], indicating that the blockade of AR signaling
disrupts the homeostatic balance between estrogen and androgen
signaling thus leading to unconstrained estrogen driven proliferation. As seen in the current study, suppression of AR function did
not influence estradiol levels or ERa expression. Thus, it is the loss
of AR signaling in the normal mammary gland under the
influence of normal hormone levels and female steroid receptor
status that increases the susceptibility of the mammary gland to
further tumor-initiating insults.
Elevated estrogen exposure is a risk factor for breast cancer
development and continuous exposure to estrogen in rodents is
sufficient to drive the formation of mammary tumors [43]. ERa
knockout (ERKO) inhibits the development of mammary tumors
in mice [18,44]. In the MMTV-NeuNT mouse model both ERa
and NeuNT are required for tumorigenesis as ERKO mice display
significant delay in the development of MMTV-NeuNT tumors.
The AR antagonizes the mitogenic activity of the estrogen
receptor [45] suggesting that AR may oppose ERa activity during
the early stages of MMTV-NeuNT driven tumorigenesis and AR
loss leads to the accelerated onset of mammary tumors.
Distinct from human breast cancers, which frequently retain
steroid receptors, mouse models of breast cancer frequently lack
steroid receptors and develop hormone independence [46,47,48].
In the present study we demonstrate that in the MMTV-NeuNT
mouse model of breast cancer the expression of AR in these
tumors is reduced. This suggests that although the AR suppresses
the formation of ERBB2 driven tumors, once these tumors are
established they may become less reliant or responsive to
androgens or ovarian hormones.
The function of ERa and AR are dependent on the pioneer
factor FOXA1 and mammary glands fail to develop in FOXA1
knockout animals [49,50]. Although the precise significance of
FOXA1 expression in breast cancer is unclear, FOXA1 expression
has been shown as a positive prognostic factor in ERa positive
tumors. A strong correlation between FOXA1 overexpression and
ERBB2 in ERa negative tumors has also been identified [51,52].
There are reports of crosstalk between FOXA1, AR and ERBB2
[52,53] and of mutual regulation of expression by FOXA1 and
ERa [49]. In the present study we demonstrate that MMTVNeuNT tumors have reduced expression of Foxa1 relative to nontumor bearing mammary glands. It would be interesting to
determine if loss of FOXA1 drives the development of hormone
independent tumors through perturbed steroid receptor signaling
or if Foxa1 expression is diminished due to the reduced expression
of ERa and/or AR.
ERBB3 overexpression and activation has been detected in
tumors from several lines of ERBB2 transgenic mice [10].
However, unlike the previous report that detected minimal
elevation in Erbb3 transcription, we note a significant up regulation
of Erbb3 mRNA in MMTV-NeuNT tumors. This indicates that in
different mouse models of ERBB2 oncogenic activation endogenous ERBB3 is selectively upregulated, although by different
mechanisms. Although mutated ERBB2 is capable of homodimerizing, ERBB2/ERBB3 heterodimers can utilize mouse growth
hormone signaling and may be required for tumorigenesis. We
also observed no increase in Erbb4 expression. This suggests that
NeuNT transformation selectively amplifies Erbb3 expression to
drive tumorigenesis.

Figure 7. MMTV-NeuNT does not affect steroid receptor
expression in normal mammary glands. MMTV-NeuNT expressing
(NeuNT) and non-expressing (WT) mammary glands were dissociated
from the fat pad. RNA was prepared as described in the materials and
methods section. Expression of NeuNT (A), Ar (B), Esr1 (C), Pr (D), and
Foxa1 (E) were analyzed by qRT-PCR (WT n = 8 and MMTV-NeuNT
n = 10). Expression of each gene was normalized to 18S. (*denotes
P,0.05).
doi:10.1371/journal.pone.0060455.g007

occur within a limited number of cells. Thus, MMTV-cre,
MMTV-NeuNT, Arfl/+ mice may be a valuable in vivo model
for ARs role in breast carcinogenesis.
In the current study, we noticed a considerable delay in the
onset of tumors in control mice (MMTV-NeuNT, Arfl/+)
compared with the incidence reported for the original parent
colony ((FVB-Tg(MMTV-ErbB2)NK1Mul/J), which reported
50% incidence in female mice by 25 weeks of age [7]. This
disparity is possibly due to differences in the genetic background of
mouse strains; the original line is on an FVB background, whereas
Arfl/fl mice are on a C57BL/6 background. C57BL/6 mice are
reported to be more resistant to multiple types of tumors
[39,40,41]. Furthermore, we observed almost no tumor development in our male cohort of mice over a period of 65 weeks. We
were interested to determine if AR deletion also affected the
susceptibility of male breast cancers, since men with partial or
complete androgen insensitivity (AIS) have an elevated risk of
breast cancer. AIS associated breast cancer risk is typically
associated with elevated estrogen exposure [42]. The lack of tumor
development in male mice was also probably due to the mixed
background utilized in the current study.
It has previously been reported that global AR knockout
increases the susceptibility of female mice to DMBA-induced
mammary tumors [26]. Increased tumor susceptibility in ARKO
females was associated with elevated proliferation of luminal
epithelial cells in virgin mice. Increased proliferation in ARKO
females was likely due to the loss of AR antagonism of ERa
signaling. In the ARKO study, mammary glands were selectively
collected at 8 weeks of age during the estrus phase of the estrous
cycle, at which time estrogens exert their largest influence. In the
present study, normal mammary glands were collected either at
sacrifice due to tumor burden or once females reached 400 days of
age independently of the estrous cycle. While we did not observe
PLOS ONE | www.plosone.org
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Diminished expression of AR in the mammary glands of female
mice leads to dramatically earlier onset of MMTV-NeuNT
induced mammary tumors. Interestingly, AR loss did not result
in an increase in the percentage of tumor-bearing mice in the
MARKO group compared to controls. Female ARKO mice do
not develop mammary tumors [26] and, in our study, neither do
female MARKO mice that do not have the MMTV-NeuNT
transgene. Thus, AR inactivation alone does not predispose the
mammary gland to mammary tumors. This indicates that the AR
opposes mammary gland transformation and its loss predisposes
mammary epithelial cells to malignant growth instigated by other
oncogenes.
MARKO tumors display the same profile as control tumors;
proliferation rate, tumor growth rate, steroid receptor and
downstream signaling profiles. In addition, Foxa1 and Erbb3/
Erbb4 expression levels are similar. Therefore it is the loss of AR
function that makes it easier for epithelial cells expressing ERBB2
to undergo malignant transformation.

and B were quantified and are shown as the percentage of Ki67
positive cells. Scale bar = 50 mm.
(TIF)
Figure S2 Steroid receptor signaling is intact in normal MMTVNeuNT expressing mammary glands. MMTV-NeuNT expressing
non-tumor bearing mammary glands from Control (n = 24) and
MARKO (n = 15) mice were dissociated from the fat pad. RNA
was analyzed for the expression of Era (A), Pr (B), Areg (C), RankL
(D), Wnt4 (E). Expression of each gene was normalized to 18S.
(TIF)

Sequences of the forward and reverse primers used for
the corresponding gene expression analysis by qPCR.
(XLSX)
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